Related Experiment Video
Updated: Jan 22, 2026

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
Published on: July 30, 2018
MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma
Xingjun Jiang1, Jun Tan2, Yin Wen2
1Department of Neurosurgery, Collaborative Innovation Center for Cancer Medicine, Xiangya Hospital, Central South University, Xiangya Road 87, Changsha, 410008, Hunan, People's Republic of China. jiangxingjun@sina.com.
Purpose:
Glioblastoma is the most malignant glioma tumors with inevitable relapse and resistance to chemotherapy; however, the mechanisms driving chemoresistance remain to be fully elucidated. This study is to explore the molecular and cellular mechanisms involving in the chemoresistance of glioblastoma.
Methods:
The expression of musashi (MSI) RNA-binding protein in the tumor tissues and cells of glioblastoma was measured. The effects of MSI2 in epithelial-to-mesenchymal transition (EMT), resistance to temozolomide (TMZ), tumor cell invasion, migration, and proliferation and associated signaling were evaluated.
Results:
High MSI2 expression was observed in the glioblastoma tissues. Silencing or overexpression of MSI2 significantly affected tumor cells invasion, migration, and proliferation. Silencing of MSI2 expression significantly inhibited O6-methylguanine-DNA methyltransferase (MGMT) expression and tumor growth, and reversed resistance to TMZ in xenograft tumor models. MSI2 expression regulated EMT through activating the transcription factors Snail and the TGFβ R1/SMAD3 signaling.
Conclusions:
Our study demonstrated a positive feedback loop of MSI2-TGFβ/SMAD3 signaling which activates the EMT and MGMT which may contribute to chemoresistance in glioblastoma. This study also highlights that MSI2 could be a new target for the therapy of glioblastoma.
Insights
Musashi RNA-binding protein 2 (MSI2) drives glioblastoma chemoresistance by activating epithelial-to-mesenchymal transition and MGMT expression. Targeting MSI2 may offer a new therapeutic strategy for glioblastoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma is a highly aggressive brain tumor known for its resistance to chemotherapy and inevitable relapse.
- The precise molecular mechanisms underlying glioblastoma chemoresistance are not fully understood, necessitating further investigation.
Purpose of the Study:
- To explore the molecular and cellular mechanisms contributing to chemoresistance in glioblastoma.
- To investigate the role of Musashi RNA-binding protein 2 (MSI2) in glioblastoma chemoresistance.
Main Methods:
- Assessed MSI2 expression in glioblastoma tissues and cells.
- Evaluated the impact of MSI2 on epithelial-to-mesenchymal transition (EMT), temozolomide (TMZ) resistance, invasion, migration, and proliferation.
- Investigated the signaling pathways regulated by MSI2, including TGFβ R1/SMAD3 and its effect on O6-methylguanine-DNA methyltransferase (MGMT).
Main Results:
- Elevated MSI2 expression was detected in glioblastoma tissues.
- MSI2 modulation significantly influenced glioblastoma cell invasion, migration, and proliferation.
- Silencing MSI2 inhibited tumor growth, reduced MGMT expression, and reversed TMZ resistance in vivo, while activating Snail and TGFβ R1/SMAD3 signaling.
Conclusions:
- A positive feedback loop involving MSI2, TGFβ/SMAD3 signaling, EMT, and MGMT contributes to glioblastoma chemoresistance.
- MSI2 represents a potential therapeutic target for overcoming chemoresistance in glioblastoma.
Related Concept Videos
TGF - β Signaling Pathway
Positive Regulator Molecules
Positive Regulator Molecules
Positive and Negative Feedback Loops
Feedback Regulation of Calcium Concentration
Various transmembrane receptors, such as G protein-coupled receptors (GPCRs), elicit a response to extracellular signals by increasing cytosolic calcium. Activated GPCRs...
Root Loci for Positive-Feedback Systems
The construction rules for the root locus in positive feedback systems are similar to those in...

